Drugs / HBV-MPL 208129
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00697840 | Jun 1995 → Jan 1996 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBV-MPL 208129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00697840 ↗ |
| Modality | Vaccine | “adjuvanted hepatitis B vaccine” NCT00697840 ↗ |
| Route | Intramuscular | “Intramuscular injection, 2 doses” NCT00697840 ↗ |